AJMC

The American Journal of #ManagedCare is a peer-reviewed, indexed publication. offers news in health policy, disease states, and managed care.

[AJMC @AJMC_Journal]

Unlike #influenza and #RSV, new wastewater data and prior research suggest COVID-19 may follow recurring spring and summer transmission patterns.

Learn more here: https://t.co/ajj8MsJ32Z

[AJMC @AJMC_Journal]

Real-world data reveal racial disparities in cancer pain medication timing and strong #opioid prescribing, with gaps most pronounced in breast and prostate cancer.

Learn more from this #AJMC interview with Ila Sruti, MPH: https://t.co/y3SVbvaZME

[AJMC @AJMC_Journal]

Stay informed on the latest in biosimilars policy, approvals, adoption, and patient access. Subscribe to The Biosimilars Bulletin and read the newest edition from The Center for Biosimilars here: https://t.co/Id5osyuA4G

#Biosimilars #HealthPolicy

[AJMC @AJMC_Journal]

The #FDA has approved its first new sunscreen ingredient in decades. #Bemotrizinol offers both #UVA and #UVB protection, lasts in sunlight, and has been used around the world for more than 20 years.

Read more: https://t.co/Xa14zDBdRv

[AJMC @AJMC_Journal]

Today marks the 10th anniversary of the Oncology Care Model (#OCM).

In this clip, Stephen Schleicher, MD, MBA, explains the improvements in care intentionality at his practice since the #OCM was first implemented.

Learn more about its impact here: https://t.co/zfv9kv3xeU

[AJMC @AJMC_Journal]

📣 It’s back. The upcoming CFB newsletter returns soon with timely biosimilar updates, expert perspectives, and essential industry coverage. Keep an eye out for it this Friday.

#Biosimilars #HealthcareNews #Biologics #Pharmacy

[AJMC @AJMC_Journal]

What is still unclear in #ProstateCancer care?
Chemo sequencing in the #ARPI era and when to use radiopharmaceuticals vs docetaxel remain open questions.

What is clear? Genetics + PSMA PET are essential.
Hear What Experts Are Saying: https://t.co/yJsU8zaROG

[AJMC @AJMC_Journal]

How do #Retina specialists translate #ClinicalTrial evidence into real-world treatment decisions? Tune in as experts discuss how patient variability, adherence, and treatment burden can influence durability and dosing intervals in practice.

Watch Here: https://t.co/ix73xoha6a

[AJMC @AJMC_Journal]

In a new study, SEER and Medicare data project rising #DLBCL and #MCL cases through 2032, intensifying payer strain and demand for Brukinsa, Calquence, and CAR-T access.

Learn more here: https://t.co/yCPJlvQZ2F

[AJMC @AJMC_Journal]

Selinexor plus ruxolitinib showed greater spleen reductions and an early survival signal in JAK-naive #myelofibrosis, Claire Harrison, MD, explained at #EHA2026.

Watch here: https://t.co/PAIH54qwaF

[AJMC @AJMC_Journal]

June is Men's Health Month, a reminder that improving health outcomes begins long before a diagnosis.

Explore the latest coverage at https://t.co/VzKxm1hSy9… (https://t.co/bZCPGVSKIA)

[AJMC @AJMC_Journal]

Public trust can shape the course of an Ebola outbreak as much as medical interventions. Learn how communication and community engagement influence response efforts.

Sign in or share a few details to continue reading: https://t.co/bWjl4zv1Dq

[AJMC @AJMC_Journal]

What comes after today’s #StrokePrevention strategies?

#Neurology experts discuss #biomarkers, DAPT limitations, bleeding risk, adherence challenges, and the future of precision neurology in this video: https://t.co/jarJOnuM0m

[AJMC @AJMC_Journal]

A new interactive microsite explores real-world data on dose modifications for adverse reactions in first-line CLL/SLL. See how clinical and economic outcomes intersect in everyday clinical practice.
View here: https://t.co/FChlXN9mUG

[AJMC @AJMC_Journal]

What's next for #CSCC treatment?

As research advances, #SystemicTherapy is driving more precise care, reduced toxicity, and better patient outcomes.

Get the expert perspective: https://t.co/9v60sT4W6E #ManagedCare

[AJMC @AJMC_Journal]

#EHA2026 highlights included practice-changing immunotherapy data in relapsed/refractory multiple myeloma and high-risk pediatric B-cell ALL, plus insights on childhood cancer predisposition.

Learn more here: https://t.co/JUfc0mdjvM

[AJMC @AJMC_Journal]

A new study found Texas's abortion ban raised the likelihood of poor maternal mental health by 2.5 points—and 7 points for mothers on Medicaid.

Learn more here: https://t.co/NY6cUudvFi

#abortion #mentalhealth

[AJMC @AJMC_Journal]

Current sickle cell disease (#SCD) trial eligibility criteria exclude most adults, with only 9.9% meeting inclusion thresholds, Julie Kanter, MD, told #AJMC at #EHA2026.

Watch here: https://t.co/xITKe5a6sw

[AJMC @AJMC_Journal]

Phase 1 BALLI-01 trial results presented at #EHA2026 by Dr Nitin Jain showed promising #UCART22 activity in R/R B-cell #ALL, with higher remission rates after a manufacturing change.

Watch his interview with #AJMC here: https://t.co/Og8XBQ93Vs

[AJMC @AJMC_Journal]

The US is close to eliminating hepatitis B in children, but chronic adult infection and a shifting vaccine policy threaten that progress.

Learn more here: https://t.co/Ig60CJ1eRi

#hepatitisB #hepB #vaccine